Company intelligence / Profile preview

Ramada

Ownership: Private
Development stage: Other

Overview

Rameda is one of Egypt’s leading pharmaceutical companies, ranked third in Egypt by three-year revenue CAGR as of 2022. It manufactures over 100 marketed branded generic pharmaceuticals across 12 key therapeutic areas with more than 270 additional products in its pipeline. The company's focus includes human health, nutraceuticals, food supplements, and veterinary medicines. Its business model centers on high-quality affordable medicines tailored to local needs.

Therapeutic areas: GastroenterologyCardiovascularMen's HealthMetabolic DisordersEndocrinologyHematologyNeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ramada.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ramada.

Explore the full profile